Status:
UNKNOWN
Predictive Value of Maternal Serum Pentraxin 3 (PTX 3) and Heparin-binding Protein (HBP) for Chorioamnionitis in Preterm Premature Rupture of Membranes
Lead Sponsor:
Second Affiliated Hospital of Wenzhou Medical University
Conditions:
Preterm Premature Rupture of Membrane
Eligibility:
FEMALE
18-40 years
Brief Summary
Objective: The aim of this study was to investigate the predictive value of maternal serum pentraxin 3 (PTX3) and heparin-binding protein (HBP) for chorioamnionitis in preterm premature rupture of mem...
Eligibility Criteria
Inclusion
- The pregnant woman is born at a gestational age of 24-40 weeks;
- The pregnant woman has a single child;
- Regular obstetric examination during pregnancy with complete obstetric examination data was diagnosed as premature rupture of membranes (PROM).
Exclusion
- Pregnancy complicated with medical and surgical diseases, such as thyroid dysfunction and chronic hypertension;
- Insufficiency of vital organ function or complicated tumor;
- Pregnant women with other pregnancy complications besides PROM, such as preeclampsia, etc.;
- Neonates had major congenital malformations (congenital anal atresia, congenital biliary atresia, congenital heart disease and so on, whether prenatal suspicion or diagnosis postpartum)
- Neonatal septicemia, hemolytic disease or other diseases affecting bilirubin metabolism.
Key Trial Info
Start Date :
February 10 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 31 2023
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT05207800
Start Date
February 10 2022
End Date
July 31 2023
Last Update
January 26 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.